Home › Funds › Pivotal bioVenture Partners Investment Advisor LLC › VRDN

Pivotal bioVenture Partners Investment Advisor LLC position in VRDN

VIRIDIAN THERAPEUTICS INC · Health Care

Pivotal bioVenture Partners Investment Advisor LLC reported holding 860,343 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$11.8M, representing 4.81% of its reported portfolio and ranking #8 among its reported holdings. Pivotal bioVenture Partners Investment Advisor LLC first reported this position in Q3 2026.

Latest position (Q3 2026)860.34K sh
Reported value held$11.81M
Portfolio Weight4.81%
First reportedQ3 2026
Last changeNew
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Pivotal bioVenture Partners Investment Advisor LLC's VRDN position evolved

Pivotal bioVenture Partners Investment Advisor LLC first disclosed a stake in VRDN in Q3 2026 at 860,343 shares (US$11.8M).

Quarter by quarter

QuarterSharesValueChange
Q3 2026 860.34K $11.81M New

About VRDN and 13F data

VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 36 other funds we track also report a position in VRDN — the largest reported positions include Bellevue Group AG (US$123.7M), Paradigm Biocapital Advisors LP (US$123.5M), Kynam Capital Management, LP (US$118.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRDN

All VRDN fund holders →

FAQ

How long has Pivotal bioVenture Partners Investment Advisor LLC held VRDN?

Pivotal bioVenture Partners Investment Advisor LLC has disclosed VRDN holdings in 1 of the last 1 reported quarters, going back to Q3 2026.

What is Pivotal bioVenture Partners Investment Advisor LLC's current position in VRDN?

As of Q3 2026, Pivotal bioVenture Partners Investment Advisor LLC holds 860.34K shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $11.81M, representing 4.81% of its reported portfolio and ranking #8.

Has Pivotal bioVenture Partners Investment Advisor LLC been buying or selling VRDN?

In the latest 13F filing (Q3 2026), Pivotal bioVenture Partners Investment Advisor LLC newly opened its position in VRDN.

Which other funds hold VRDN?

Other major institutional holders of VRDN include Bellevue Group AG, Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, among 36 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.